Efficacy and Safety With Ziprasidone in First-episode Psychosis
NCT ID: NCT01157559
Last Updated: 2010-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
27 participants
INTERVENTIONAL
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Ziprasidone for Patients With Schizophrenia
NCT01198353
Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia
NCT01260116
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
NCT01006551
Efficacy and Safety of Paliperidone ER in First Episode Psychosis
NCT01157585
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
NCT00159770
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ziprasidone
8 week prospective study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients with substance-induced psychotic disorder, serious suicide attempt, neurological disorder, etc.
14 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chonbuk National University Hospital, Jeonju, Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, Chonbuk national University Hospital
Jeonju, , South Korea
Heo psychiatric Hospital
Jeonju, , South Korea
Jeonju Jesus Hospital
Jeonju, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-Zeldox in FEP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.